Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma

Daniel W Visscher, F. Sarkar, P. Tabaczka, J. Crissman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tissue sections of 81 breast carcinomas and 19 benign breast tissues were immunostained with a monoclonal antibody to the bcl-2 gene product, a cytoplasmic protein that regulates apoptosis. The degree of immunoreactivity was then compared with clinicopathologic parameters and to immunostaining for mutated p53 gene product. Immunoreactivity for bcl-2 was present consistently in lymphocyte populations and in residual benign lobules. Apocrine metaplasia (n = 6) and lactating breast (n = 1) exhibited minimal bcl-2 expression, whereas duct hyperplasia (n = 10) showed staining of cells primarily at the periphery of the involved structure and adenosis (n = 7) displayed staining in a majority of cells. Neoplastic epithelial bcl-2 immunoreactivity was negative or minimally positive (staining in 1-5% of cells) in 42% of cases, heterogeneous (staining in 6-30% of cells) in 27% of cases, and diffuse (> 30% of cells) in 31% of cases. Immunostaining for bcl-2 correlated with the presence of estrogen receptor (bcl-2 negative, 16% estrogen receptor positive versus bcl-2 positive, 88% estrogen receptor-positive; P < 0.001), with differentiation (bcl-2 negative, 62% poorly differentiated versus bcl-2 positive, 8% poorly differentiated; P < 0.001) and with better disease-free survival (bcl-2 negative, 82% recurrence versus bcl-2 positive, 28% recurrence; P = 0.0001; 52-mo mean follow-up). Immunostaining for p53 in greater than 5% of tumor cells was observed in 39% of cases and was more frequent in bcl-2-negative tumors (18/35, 51%) as opposed to bcl-2-positive tumors (14/46, 30%); P = NS. Disease recurrence correlated with p53 staining, which was observed in 51% of tumors that relapsed versus only 22% of tumors that did not recur. We conclude that bcl-2 is expressed in benign breast tissues that retain proliferative capacity and partial differentiation. Moreover, in neoplastic breast tissue, it is better correlated with a differentiated, 'hormonally responsive,' prognostically favorable phenotype than with disabled p53 gene function.

Original languageEnglish (US)
Pages (from-to)642-646
Number of pages5
JournalModern Pathology
Volume9
Issue number6
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Breast Neoplasms
Staining and Labeling
Breast
p53 Genes
Neoplasms
Recurrence
Estrogen Receptors
bcl-2 Genes
Estrogen Receptor beta
Metaplasia
Disease-Free Survival
Hyperplasia
Monoclonal Antibodies
Lymphocytes
Apoptosis
Phenotype
Population
Proteins

Keywords

  • bcl-2
  • Breast carcinoma
  • Immunohistology
  • p53

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Visscher, D. W., Sarkar, F., Tabaczka, P., & Crissman, J. (1996). Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Modern Pathology, 9(6), 642-646.

Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. / Visscher, Daniel W; Sarkar, F.; Tabaczka, P.; Crissman, J.

In: Modern Pathology, Vol. 9, No. 6, 06.1996, p. 642-646.

Research output: Contribution to journalArticle

Visscher, DW, Sarkar, F, Tabaczka, P & Crissman, J 1996, 'Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma', Modern Pathology, vol. 9, no. 6, pp. 642-646.
Visscher, Daniel W ; Sarkar, F. ; Tabaczka, P. ; Crissman, J. / Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. In: Modern Pathology. 1996 ; Vol. 9, No. 6. pp. 642-646.
@article{a267b02b959344ffa1577c83ccfb44b3,
title = "Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma",
abstract = "Tissue sections of 81 breast carcinomas and 19 benign breast tissues were immunostained with a monoclonal antibody to the bcl-2 gene product, a cytoplasmic protein that regulates apoptosis. The degree of immunoreactivity was then compared with clinicopathologic parameters and to immunostaining for mutated p53 gene product. Immunoreactivity for bcl-2 was present consistently in lymphocyte populations and in residual benign lobules. Apocrine metaplasia (n = 6) and lactating breast (n = 1) exhibited minimal bcl-2 expression, whereas duct hyperplasia (n = 10) showed staining of cells primarily at the periphery of the involved structure and adenosis (n = 7) displayed staining in a majority of cells. Neoplastic epithelial bcl-2 immunoreactivity was negative or minimally positive (staining in 1-5{\%} of cells) in 42{\%} of cases, heterogeneous (staining in 6-30{\%} of cells) in 27{\%} of cases, and diffuse (> 30{\%} of cells) in 31{\%} of cases. Immunostaining for bcl-2 correlated with the presence of estrogen receptor (bcl-2 negative, 16{\%} estrogen receptor positive versus bcl-2 positive, 88{\%} estrogen receptor-positive; P < 0.001), with differentiation (bcl-2 negative, 62{\%} poorly differentiated versus bcl-2 positive, 8{\%} poorly differentiated; P < 0.001) and with better disease-free survival (bcl-2 negative, 82{\%} recurrence versus bcl-2 positive, 28{\%} recurrence; P = 0.0001; 52-mo mean follow-up). Immunostaining for p53 in greater than 5{\%} of tumor cells was observed in 39{\%} of cases and was more frequent in bcl-2-negative tumors (18/35, 51{\%}) as opposed to bcl-2-positive tumors (14/46, 30{\%}); P = NS. Disease recurrence correlated with p53 staining, which was observed in 51{\%} of tumors that relapsed versus only 22{\%} of tumors that did not recur. We conclude that bcl-2 is expressed in benign breast tissues that retain proliferative capacity and partial differentiation. Moreover, in neoplastic breast tissue, it is better correlated with a differentiated, 'hormonally responsive,' prognostically favorable phenotype than with disabled p53 gene function.",
keywords = "bcl-2, Breast carcinoma, Immunohistology, p53",
author = "Visscher, {Daniel W} and F. Sarkar and P. Tabaczka and J. Crissman",
year = "1996",
month = "6",
language = "English (US)",
volume = "9",
pages = "642--646",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma

AU - Visscher, Daniel W

AU - Sarkar, F.

AU - Tabaczka, P.

AU - Crissman, J.

PY - 1996/6

Y1 - 1996/6

N2 - Tissue sections of 81 breast carcinomas and 19 benign breast tissues were immunostained with a monoclonal antibody to the bcl-2 gene product, a cytoplasmic protein that regulates apoptosis. The degree of immunoreactivity was then compared with clinicopathologic parameters and to immunostaining for mutated p53 gene product. Immunoreactivity for bcl-2 was present consistently in lymphocyte populations and in residual benign lobules. Apocrine metaplasia (n = 6) and lactating breast (n = 1) exhibited minimal bcl-2 expression, whereas duct hyperplasia (n = 10) showed staining of cells primarily at the periphery of the involved structure and adenosis (n = 7) displayed staining in a majority of cells. Neoplastic epithelial bcl-2 immunoreactivity was negative or minimally positive (staining in 1-5% of cells) in 42% of cases, heterogeneous (staining in 6-30% of cells) in 27% of cases, and diffuse (> 30% of cells) in 31% of cases. Immunostaining for bcl-2 correlated with the presence of estrogen receptor (bcl-2 negative, 16% estrogen receptor positive versus bcl-2 positive, 88% estrogen receptor-positive; P < 0.001), with differentiation (bcl-2 negative, 62% poorly differentiated versus bcl-2 positive, 8% poorly differentiated; P < 0.001) and with better disease-free survival (bcl-2 negative, 82% recurrence versus bcl-2 positive, 28% recurrence; P = 0.0001; 52-mo mean follow-up). Immunostaining for p53 in greater than 5% of tumor cells was observed in 39% of cases and was more frequent in bcl-2-negative tumors (18/35, 51%) as opposed to bcl-2-positive tumors (14/46, 30%); P = NS. Disease recurrence correlated with p53 staining, which was observed in 51% of tumors that relapsed versus only 22% of tumors that did not recur. We conclude that bcl-2 is expressed in benign breast tissues that retain proliferative capacity and partial differentiation. Moreover, in neoplastic breast tissue, it is better correlated with a differentiated, 'hormonally responsive,' prognostically favorable phenotype than with disabled p53 gene function.

AB - Tissue sections of 81 breast carcinomas and 19 benign breast tissues were immunostained with a monoclonal antibody to the bcl-2 gene product, a cytoplasmic protein that regulates apoptosis. The degree of immunoreactivity was then compared with clinicopathologic parameters and to immunostaining for mutated p53 gene product. Immunoreactivity for bcl-2 was present consistently in lymphocyte populations and in residual benign lobules. Apocrine metaplasia (n = 6) and lactating breast (n = 1) exhibited minimal bcl-2 expression, whereas duct hyperplasia (n = 10) showed staining of cells primarily at the periphery of the involved structure and adenosis (n = 7) displayed staining in a majority of cells. Neoplastic epithelial bcl-2 immunoreactivity was negative or minimally positive (staining in 1-5% of cells) in 42% of cases, heterogeneous (staining in 6-30% of cells) in 27% of cases, and diffuse (> 30% of cells) in 31% of cases. Immunostaining for bcl-2 correlated with the presence of estrogen receptor (bcl-2 negative, 16% estrogen receptor positive versus bcl-2 positive, 88% estrogen receptor-positive; P < 0.001), with differentiation (bcl-2 negative, 62% poorly differentiated versus bcl-2 positive, 8% poorly differentiated; P < 0.001) and with better disease-free survival (bcl-2 negative, 82% recurrence versus bcl-2 positive, 28% recurrence; P = 0.0001; 52-mo mean follow-up). Immunostaining for p53 in greater than 5% of tumor cells was observed in 39% of cases and was more frequent in bcl-2-negative tumors (18/35, 51%) as opposed to bcl-2-positive tumors (14/46, 30%); P = NS. Disease recurrence correlated with p53 staining, which was observed in 51% of tumors that relapsed versus only 22% of tumors that did not recur. We conclude that bcl-2 is expressed in benign breast tissues that retain proliferative capacity and partial differentiation. Moreover, in neoplastic breast tissue, it is better correlated with a differentiated, 'hormonally responsive,' prognostically favorable phenotype than with disabled p53 gene function.

KW - bcl-2

KW - Breast carcinoma

KW - Immunohistology

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0029948602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029948602&partnerID=8YFLogxK

M3 - Article

C2 - 8782201

AN - SCOPUS:0029948602

VL - 9

SP - 642

EP - 646

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 6

ER -